Skip to main content

Table 1 Previous reports of treatment with tocilizumab in systemic sclerosis patients with or without rheumatoid arthritis

From: Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature

Author Shima Y, Fernandes das NM Frech TM Shima Y Khanna D Elhai M Saito E Kono M Presentcases
Reference (Year) Ref10 (2010) Ref11 (2015) Ref12 (2015) Ref13 (2015) Ref14 (2016) Ref15 (2013) ref16 (2014) ref17 (2017) 2018
Diagnosis SSc SSc, (P3 SSc/RA) SSc SSc SSc SSc/Arthritis SSc/RA SSc/RA SSc/RA
Country (centers) Japan Portugal USA Japan USA EULAR Japan Japan Japan
Number of patients (n) 2 3 2 1 43 15 1 2 2
Age, years (SD or range) 42, 57 55, 42, 54 56, 68 59 51 ± 11.7 56 (45–61) 57 25, 32 74, 65
Duration of SSc, years (SD or range) 2, 3 3, 8, 1 ns, 0.25 4 1.46 ± 1.16 5 (4–9) 2.5 2, 3 1, 6
Durationof RA, years        2.5 0.25, 3 12, 38
Female, n (%) 1 (50%) 3 (100%) 2 (100%) 1 (100%) 32 (74%) 13 (86.7%) 1 (100%) 1 (50%) 2 (100%)
Anti-nuclear antibody 2 (100%) 3 (100%) 2 (100%) +    + 2 (100%) 2 (100%)
Anti-RNA polymerase antibody    P1+, P2- + 13 (30%)     
Anti-topoisomerase antibody P1-, P2+ P1-, P2+, P3+   18 (42%) 10 (76.9%)   P1+, P2- P2:U1-RNP+ P1-, P2+
Anti-centromere antibody      1 (7.7%)    P1+, P2-
Anti-CCP antibody   P1-, P2-, P3+     3 (37.5%) + 2 (100%) 2 (100%)
Rheumatoid factor   P1-, P2-, P3+     3 (37.5%) +   2 (100%)
Previous biological drugs   P3: ADA, ETN     RTX:3, ABT:1, TNF: 2 IFX   
Immunosuppressive drugs P1: CyA P1: CyA,AZA,HCQ
P2: CyA,AZA
P3: MTX,HCQ
   22 (51%) MTX: 8 (57.1%) MTX, TAC, SASP P1: IVCY,TAC
P2: SASP
P1: MTX, SASP
P2: CyA
Concomitant systemic corticosteroid use 2 (100%) 3 (100%)   + 21 (49%) 11 pts. (73.3%) [≤10 mg]   2 (100%) 2 (100%)
Follow-up (months) 6 6 several, 26 16 12 5 (3 to 11.5) 9 12 18
Tocilizumab dose 8 mg/kg/4 w iv 8 mg/kg/4 w iv ns 8 mg/kg/4 w iv 162 mg/w 8 mg/kg/month iv 600 mg/month P1: iv, P2: sc 162 mg/2 w
mRSS baseline 27, 26 17, 41, 7 22, 27 35 26.4 ± 7.2 15 (4.5 to 24.0)   25, 14 23, 15
mRSS last infusion 13, 20 11, 25, 5 17, 6 7 19.6 ± 10.1 12 (3.8 to 16.3) Not improved 8, 5 3, 7
DAS baseline   P3: 3.82     5.2 (3.9 to 6.1) 5.39 2.92, 6.92 5.66, 7.14
DAS last infusion   P3: 2.87     2.8 (2.2 to 3.4) 1.53 1.76, 1.1 1.10, 3.70
PGA baseline   70, 70, 60        75, 68
PGA last infusion   40, 30, 10        4, 36
Discontinued for lack of efficacy      1 (2.3%) 2 (13.3%)    
Discontinued for adverse events    1(gastroenterology)   5 (11.6%)     
  1. P1–3 patients 1–3, iv intravenous, sc subcutaneous, ns not shown
  2. CyA cyclosporine, AZA azathioprine, HCQ hydroxychloroquine, MTX methotrexate, IVCY intravenous cyclophosphamide, TAC tacrolimus, ADA adalimumab, ETN etanercept, IFX infliximab, TNF tumor necrosis factor, RTX rituximab, ABT abatacept, DAS disease activity score, PGA patient global assessment